title: Effects of FR145237, an acyl-CoA:cholesterol acyltransferase inhibitor, on diet-induced hypercholesterolemia in diabetic rats.
abstract: Recent studies have shown that acyl-CoA:cholesterol acyltransferase (ACAT) plays an important role in the initiation of diabetes-associated hypercholesterolemia. To confirm this hypothesis, effects of a potent ACAT inhibitor, FR145237, on diet-induced hypercholesterolemia were examined in streptozotocin (STZ)-induced diabetic rats. One-week feeding of 1% cholesterol and 0.5% cholic acid to normal rats and STZ-induced diabetic rats increased plasma cholesterol levels in both groups, and the response was more remarkable in the STZ rats than in the normal ones (1266 +/- 476 mg/dl and 146 +/- 7 mg/dl, respectively). FR145237 dose-dependently reduced the rise in plasma cholesterol levels in the STZ rats and the levels were almost normalized by treatment with 1 mg/kg/day of the compound. These results suggest that hyperresponse to dietary cholesterol was induced in the STZ rats and that ACAT is involved in the hyperresponse. The effects of FR145237 on other plasma lipids such as high density lipoprotein (HDL) cholesterol and triglyceride (TG) levels were also examined.
authors.affiliation: Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Ibaraki, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Sakuma
authors.forename: H
authors.initials: H
authors.lastname: Hagihara
authors.forename: A
authors.initials: A
authors.lastname: Nagayoshi
authors.forename: K
authors.initials: K
authors.lastname: Ohne
authors.forename: S
authors.initials: S
authors.lastname: Mutoh
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Nakahara
authors.forename: Y
authors.initials: Y
authors.lastname: Notsu
authors.forename: M
authors.initials: M
authors.lastname: Okuhara
mesh_terms: D000818:Animals; D001572:Benzofurans / Q000494:pharmacology*; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D008076:Cholesterol, HDL / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000201:enzymology; D004435:Eating / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology*; D008297:Male; D010671:Phenylurea Compounds / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood
chemical_list: D001572:Benzofurans; D001786:Blood Glucose; D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D004791:Enzyme Inhibitors; C097564:FR 145237; D010671:Phenylurea Compounds; D014280:Triglycerides; D002784:Cholesterol; D002785:Sterol O-Acyltransferase